Equibles does not estimate personal net worth.
Get an email with a short summary when Processa Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get PCSA alertsDavid Young is recorded as Board Member at Processa Pharmaceuticals, Inc. (PCSA) since January 1, 2017. The newest filing on record that lists David Young as Board Member at Processa Pharmaceuticals, Inc. (PCSA) is dated June 18, 2026. The proxy statement of Processa Pharmaceuticals, Inc. reports total compensation of $305,424 for David Young in fiscal 2024, including a base salary of $290,940. Disclosed compensation is on record for 6 fiscal years. David Young has spoken on 8 earnings calls across 1 company, most recently for Processa Pharmaceuticals, Inc. on March 31, 2023. Processa Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Processa Pharmaceuticals, Inc. includes George Ng (CEO and Board Member), Russell L. Skibsted (CFO), Russell Skibsted (CFO) and 7 others.
“As Jim mentioned, at the end of 2022, we recognized that it would be beneficial for our investors to concentrate on a few drugs rather than our five-drug portfolio.”
“Prior to the filing of our 10-Q for the third quarter, we had some great news on two of our drugs, which has been shared in press releases over the last eight days.”
“Before I provide a quarterly update, I’d like to thank all of our staff and shareholders for their loyalty and support.”
“Today, I plan to highlight what we’ve accomplished in the first quarter of 2022 in our drug development programs and share what you should be expecting over the next nine months.”
“During my time with you today, I plan to highlight what we’ve accomplished in 2021 in our drug development programs and briefly share what you should be expecting over the next 12 months.”
2017-01-01–present
Last confirmed June 18, 2026
Proxy statement
Start not stated–present
Last confirmed June 18, 2026
Start not stated–2023-05-01
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
Board Member
2017-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Processa Pharmaceuticals, Inc. (PCSA) | President, Research and Development and former Chief Executive Officer | $290,940 | $305,424 |
| 2023 | Processa Pharmaceuticals, Inc. (PCSA) | President, Research and Development and former Chief Executive Officer | $160,200 | $186,633 |
| 2022 | Processa Pharmaceuticals, Inc. (PCSA) | President, Research and Development and former Chief Executive Officer | $93,875 | $1,162,619 |
| 2021 | Processa Pharmaceuticals, Inc. (PCSA) | Chief Executive Officer | $87,500 | $434,512 |
| 2020 | Processa Pharmaceuticals, Inc. (PCSA) | Chief Executive Officer | $58,333 | $438,385 |
| 2019 | Processa Pharmaceuticals, Inc. (PCSA) | Chief Executive Officer | — | $163,202 |
